Severe hyperlipidemia in apolipoprotein E2 homozygotes due to a combined effect of hyperinsulinemia and an SstI polymorphism

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 11, 1999, Pages 2722-2729

  Sijbrands, Eric J G ^a,d   Hoffer, Mariëtte J V ^b   Meinders, A Edo ^a   Havekes, Louis M ^c   Frants, Rune R ^b   Smelt, Augustinus H M ^a   De Knijff, Peter ^b  

^a Leids Universitair   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TNO   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Apolipoprotein E; Hyperinsulinemia; Hyperlipoproteinemia type III; Xanthomas

Indexed keywords

APOLIPOPROTEIN E2; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE CLUSTER; GENETIC POLYMORPHISM; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; LIPOLYSIS; MALE; MULTIFACTORIAL INHERITANCE; PRIORITY JOURNAL; RISK FACTOR; XANTHOMA;

EID: 0032747981     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.11.2722     Document Type: Article

References (51)

1. Brown MS, Goldstein JL. Koch's postulates for cholesterol. Cell. 1992;71:187-188.
2. Vermeer BJ, Van Gent CM, Goslings B, Polano MK. Xanthomatosis and other clinical findings in patients with elevated levels of very low density lipoproteins. Br J Dermatol. 1979;100:657-666.
3. Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York, NY: McGraw-Hill; 1995:1953-1980.
4. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988;8:1-21.
5. Innerarity TL, Weisgraber KH, Arnold KS, Rall SC Jr, Mahley RW. Normalization of receptor binding of apolipoprotein E2: evidence for modulation of the binding site conformation. J Biol Chem. 1984;259:7261-7267.
6. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine inter-change at a single site. J Biol Chem. 1982;257:2518-2521.
7. Utermann G, Hees M, Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature. 1977;269:604-607.
8. Utermann G, Vogelberg KH, Steinmetz A, Schoenborn W, Pruin N, Jaeschke M, Hees M, Canzler H. Polymorphism of apolipoprotein E, II: genetics of hyperlipoproteinemia type III. Clin Genet. 1979;15:37-62.
9. Utermann G. Apolipoprotein E polymorphism in health and disease. Am Heart J. 1987;113:433-440.
10. Glucck CJ, Levy RI, Fredrickson DS. Immunoreactive insulin, glucose tolerance, and carbohydrate inducibility in types II, III, IV, and V hyperlipoproteinemia. Diabetes. 1969;18:739-747.
11. Duell PB, Bierman EL. Potential role of insulin in the clearance of remnant lipoproteins in dysbetalipoproteinaemia. J Intern Med. 1991;229:97-101.
12. Feussner G, Ziegler R. Expression of type III hyperlipoproteinaemia in a subject with secondary hypothyroidism bearing the apolipoprotein E2/2 phenotype. J Intern Med. 1991;230:183-186.
13. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins: an integrated approach to mechanisms and disorders. N Engl J Med. 1967;276:34-42.
14. Kolterman OG, Insel J, Sackow M, Olefsky JM. Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects. J Clin Invest. 1980;65:1272-1284.
15. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
16. Zhang H, Reymer PW, Liu MS, Forsythe IJ, Groenemeyer BE, Frohlich J, Brunzell JD, Kastelein JJP, Hayden MR, Ma Y. Patients with apoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291→Ser mutation in the human LPL gene. Arterioscler Thromb Vasc Biol. 1995;15:1695-1703.
17. Mailly F, Tugrul Y, Reymer PW, Bruin T, Seed M, Groenemeyer BF, Asplund-Carlson A, Vallance BD, Winder AF, Miller GJ, Kastelein JJP, Hamsten A, Olivecrona G, Humphries SE, Talmud PJ. A common variant in the gene for lipoprotein lipase (Asp9→Asn). Functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol. 1995;15:468-478.
18. Fisher RM, Mailly F, Peacock RE, Hamsten A, Seed M, Yudkin JS, Beisiegel U, Feussner G, Miller G, Humphries SE, Talmud PJ. Interaction of the lipoprotein lipase asparagin 291-serine mutation with body mass index determines elevated plasma triacylglycerol concentrations: a study in hyperlipidemic subjects, myocardial infarction survivors, and healthy adults. J Lipid Res. 1995;36:2104-2112.
19. Hoffer MJV, Bredie SJH, Boomsma DI, Reymer PW, Kastelein JJP, De Knijff P, Demacker PNM, Stalenhoef AFH, Havekes LM, Fronts RR. The lipoprotein lipase (Asn291→Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidaemia. Atherosclerosis. 1996;119:159-167.
20. 447stop mutation in lipoprotein lipase is associated with elevated HDL cholesterol levels in normolipidemic males. Arterioscler Thromb Vasc Biol. 1997;17:595-599.
21. Thuren T, Weisgraber KH, Sisson P, Waite M. Role of apolipoprotein E in hepatic lipase catalyzed hydrolysis of phospholipid in high-density lipoproteins. Biochemistry. 1992;31:2332-2338.
22. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein C-III. J Clin Invest. 1985;75:384-390.
23. Windier E, Havel RS. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 1985;26:556-565.
24. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA. 1993;90:4562-4566.
25. Ebara T, Ramakrishnan R, Steiner G, Schachter NS. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice: apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest. 1997;99:2672-2681.
26. Rees A, Shoulders CC, Stocks J, Galton DJ, Baralle FE. DNA polymorphisms adjacent to human apoprotein A-1 gene: relation to hypertriglyceridaemia. Lancet. 1983;1:444-446.
27. Rees A, Stocks J, Sharpe CR, Vella MA, Shoulders CC, Katz J, Jowett NI, Baralle FE, Galton DJ. Deoxyribonucleic acid polymorphism in the apolipoprotein A-1-C-III gene cluster. J Clin Invest. 1985;76:1090-1095.
28. Ferns GA, Stocks J, Ritchie C, Galton DJ. Genetic polymorphisms of apolipoprotein C-III and insulin in survivors of myocardial infarction Lancet. 1985;2:300-303.
29. Tybjaerg-Hansen A, Nordestgaard BG, Gerdes LU, Faergeman O, Humphries SE. Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis. Atherosclerosis. 1993;100:157-169.
30. Hoffer MJV, Sijbrands EJG, De Man FHAF, Havekes LM, Smelt AHM, Frants RR. Increased risk for endogenous hypertriglyceridaemia is associated with an apolipoprotein C3 haplotype specified by the SstI polymorphism. Eur J Clin Invest. 1998;28:807-812.
31. Ferns GAA, Galton DJ. Haplotypes of the human apoprotein AI-CIII-AIV gene cluster in coronary atherosclerosis. Hum Genet. 1986;73:245-249.
32. Shoulders CC, Grantham TT, North JD, Gaspardone A, Tomai F, De Fazio A, Versaci F, Gioffre PA, Cox NJ. Hypertriglyceridemia and the apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian school children. Hum Genet. 1996;98:557-566.
33. Surguchov AP, Page GP, Smith L, Patsch W, Boerwinkle E. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1996;16:941-947.
34. Havekes LM, De Knijff P, Beisiegel U, Havinga J, Smit M, Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res. 1987;28:455-463.
35. Reymer PW, Groenemeyer BE, Van den Burg R, Kastelein JJP. Apolipoprotein E genotyping on agarose gels. Clin Chem. 1995;41:1046-1047.
36. Smit M, De Knijff P, Rosseneu M, Bury J, Klasen E, Frants RR, Havekes LM. Apolipoprotein E polymorphism in the Netherlands and its effect on plasma lipid and apolipoprotein levels. Hum Genet. 1988;80:287-292.
37. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137:959-965.
38. Sijbrands EJG, Westendorp RGJ, Hoffer MJV, Frants RR, Meinders AE, Souverijn JHM, Gevers Leuven JA, van der Laarse A, Havekes LM, Smelt AHM. Effect of apolipoprotein E and insulin resistance on VLDL particles in combined hyperlipidemic patients. Atherosclerosis. 1996;126:197-205.
39. Stocks J, Thorn JA, Galton DJ. Lipoprotein lipase genotypes for a common premature termination codon mutation detected by PCR-mediated site-directed mutagenesis and restriction digestion. J Lipid Res. 1992;33:853-857.
40. Hegele RA, Tu L, Connelly PW. Human hepatic lipase mutations and polymorphisms. Hum Mutat. 1992;1:320-324.
41. Li WW, Dammerman M, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest. 1995;96:2601-2605.
42. Wang XL, Badenhop R, Humphrey KE, Wilcken DEL. New MspI polymorphism at + 83 bp of the human apolipoprotein AI gene: association with increased circulating high density lipoprotein cholesterol levels. Genet Epidemiol. 1996;13:1-10.
43. Long JC, Williams RC, Urbanck M. An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet. 1995;56:799-810.
44. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R. Insulin sensitivity and atherosclerosis. Circulation. 1996;93:1809-1817.
45. Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischaemic heart disease. N Engl J Med. 1996;334:952-957.
46. Sijbrands EJG, Westendorp RGJ, Hoffer MJV, Havekes LM, Frants RR, Meinders AE, Frölich M, Smelt AHM. Effect of insulin resistance, apoE2 allele, and smoking on combined hyperlipidemia. Arterioscler Thromb. 1994;14:1576-1580.
47. Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med. 1974;57:551-560.
48. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stem MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41:715-722.
49. Bruce R, Godsland I, Walton C, Cook D, Wynn V. Associations between insulin sensitivity, and free fatty acid and triglyceride metabolism independent of uncomplicated obesity. Metabolism. 1994;43:1275-1281.
50. Thiebaud D, DeFronzo RA, Jacot E, Golay A, Acheson K, Maeder E, Jequier E, Felber JP. Effect of long chain triglyceride infusion on glucose metabolism in man. Metabolism. 1982;31:1128-1136.
51. Reaven GM, Mondon CE, Chen YD, Breslow JL. Hypertriglyceridemic mice transgenic for the human apolipoprotein C-III gene are neither insulin resistant nor hyperinsulinemic. J Lipid Res. 1994;35:820-824.